Gastrointestinal Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal Carcinoma

MalaCards integrated aliases for Gastrointestinal Carcinoma:

Name: Gastrointestinal Carcinoma 12 54 6 15 71
Gastrointestinal Neoplasms 71


External Ids:

Disease Ontology 12 DOID:0050922
UMLS 71 C0017185 C0151544

Summaries for Gastrointestinal Carcinoma

Disease Ontology : 12 A gastrointestinal system cancer that has material basis in epithelial cells.

MalaCards based summary : Gastrointestinal Carcinoma, also known as gastrointestinal neoplasms, is related to neutropenia and adenoma, and has symptoms including signs and symptoms, digestive An important gene associated with Gastrointestinal Carcinoma is CHEK2 (Checkpoint Kinase 2), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Aspirin and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and colon, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Wikipedia : 74 Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract (GI tract) and... more...

Related Diseases for Gastrointestinal Carcinoma

Diseases related to Gastrointestinal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 317)
# Related Disease Score Top Affiliating Genes
1 neutropenia 30.3 TYMS TP53 ITGAL DPYD
2 adenoma 30.1 TP53 MUC1 KRT20 CDX2
3 rectum cancer 30.1 TYMS KRT20 DPYD CEACAM7 CEACAM5
4 papilloma 29.9 TYMS TP53 KRT20 CHEK2
5 mucositis 29.9 TYMS MMP2 DPYD CD44
6 pancreatic ductal carcinoma 29.8 TP53 MUC1 KRT20 CEACAM7
7 basal cell carcinoma 29.8 TP53 KRT20 KRT19 CHEK2 CEACAM5
8 pancreatic ductal adenocarcinoma 29.7 TP53 MUC1 KRT19 CD44
9 microinvasive gastric cancer 29.6 TP53 GAST CEACAM5 CDX2
10 transitional cell carcinoma 29.5 TP53 KRT20 KRT19 CD44
11 intrahepatic cholangiocarcinoma 29.5 TP53 MUC1 KRT20 KRT19 EPCAM CDX2
12 villous adenoma 29.5 TP53 MUC1 KRT20 CEACAM5 CDX2
13 pseudomyxoma peritonei 29.3 TP53 MUC1 KRT20 EPCAM CEACAM5 CDX2
14 colon adenocarcinoma 29.2 TYMS TP53 MMP2 KRT20 EPCAM CEACAM7
15 adenocarcinoma 29.1 TP53 MUC1 MMP2 KRT20 EPCAM CEACAM6
16 bile duct cancer 29.1 TP53 MUC1 MMP2 KRT19 CEACAM5 CDX2
17 neuroendocrine carcinoma 29.0 PTPRC MUC1 KRT20 KRT19 GAST CEACAM5
18 squamous cell carcinoma 28.6 TP53 MUC1 MMP2 KRT19 EPCAM CHEK2
19 esophageal cancer 28.6 TYMS TP53 MUC1 MMP2 KRT19 EPCAM
20 colorectal adenocarcinoma 28.6 TYMS TP53 MUC1 MMP2 KRT20 CEACAM5
21 small cell carcinoma 28.5 TP53 PTPRC MUC1 KRT20 KRT19 GAST
22 gallbladder cancer 28.3 TYMS TP53 MUC1 MMP2 KRT20 KRT19
23 cholangiocarcinoma 28.0 TP53 MUC1 KRT20 KRT19 CEACAM6 CEACAM5
24 pancreatic adenocarcinoma 27.9 TP53 MUC1 MMP2 KRT19 GAST EPCAM
25 pancreatic cancer 27.6 TYMS TP53 MUC1 MMP2 KRT20 KRT19
26 gastric adenocarcinoma 27.3 TYMS TP53 MUC1 MMP2 KRT20 GAST
27 gastric cancer 26.7 TYMS TP53 MUC1 MMP2 KRT20 KRT19
28 colorectal cancer 26.5 TYMS TP53 MUC1 MMP2 KRT20 KRT19
29 larynx sarcoma 10.6 EPCAM CEACAM5
30 urethral villous adenoma 10.5 KRT20 CEACAM5
31 fibroepithelial basal cell carcinoma 10.5 KRT20 CEACAM5
32 intratubular embryonal carcinoma 10.5 TP53 KRT20
33 pancreatic serous cystadenocarcinoma 10.5 KRT20 CEACAM5
34 intrahepatic bile duct adenoma 10.5 KRT20 KRT19
35 bile duct mucinous adenocarcinoma 10.5 TP53 MUC1
36 mucoepidermoid esophageal carcinoma 10.5 TP53 CEACAM5
37 rectosigmoid junction neoplasm 10.5 KRT20 CEACAM5
38 sigmoid neoplasm 10.5 KRT20 CEACAM5
39 gastric signet ring cell adenocarcinoma 10.5 KRT20 CDX2
40 seminal vesicle adenocarcinoma 10.5 KRT20 CDX2
41 malignant syringoma 10.5 KRT20 CEACAM5
42 papillary transitional carcinoma 10.5 TP53 KRT20
43 vulvar eccrine porocarcinoma 10.5 MUC1 CEACAM5
44 eccrine porocarcinoma 10.5 MUC1 CEACAM5
45 transverse colon cancer 10.5 KRT20 CEACAM5
46 nodular hidradenoma 10.5 MUC1 CEACAM5
47 thymus lipoma 10.5 KRT20 KRT19
48 gallbladder leiomyosarcoma 10.5 TYMS KRT19
49 lipid-rich breast carcinoma 10.5 MUC1 CEACAM5
50 immune system organ benign neoplasm 10.5 KRT20 KRT19

Graphical network of the top 20 diseases related to Gastrointestinal Carcinoma:

Diseases related to Gastrointestinal Carcinoma

Symptoms & Phenotypes for Gastrointestinal Carcinoma

UMLS symptoms related to Gastrointestinal Carcinoma:

signs and symptoms, digestive

MGI Mouse Phenotypes related to Gastrointestinal Carcinoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.81 CD44 CDX2 CEACAM1 DPYD EPCAM GAST
2 endocrine/exocrine gland MP:0005379 9.61 CD44 CDX2 CEACAM1 CHEK2 EPCAM GAST
3 neoplasm MP:0002006 9.32 CD44 CDX2 CEACAM1 CHEK2 GAST ITGAL

Drugs & Therapeutics for Gastrointestinal Carcinoma

Drugs for Gastrointestinal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 286)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
parecoxib Approved Phase 4 198470-84-7
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Insulin glargine Approved Phase 4 160337-95-1
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
Enoxaparin Approved Phase 4 9005-49-6 772
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
15 Fibrinolytic Agents Phase 4
16 Cyclooxygenase Inhibitors Phase 4
17 Platelet Aggregation Inhibitors Phase 4
18 Antipyretics Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Cyclooxygenase 2 Inhibitors Phase 4
21 Anti-Arrhythmia Agents Phase 4
22 Insulin, Globin Zinc Phase 4
23 insulin Phase 4
24 Neuromuscular Blocking Agents Phase 4
25 Hypoglycemic Agents Phase 4
26 Anticonvulsants Phase 4
27 calcium channel blockers Phase 4
28 Tocolytic Agents Phase 4
29 glutamine Phase 4
30 Anticoagulants Phase 4
31 Respiratory System Agents Phase 4
32 Adrenergic Agents Phase 4
33 Anti-Inflammatory Agents Phase 4
34 Antineoplastic Agents, Hormonal Phase 4
35 Gastrointestinal Agents Phase 4
36 Hormone Antagonists Phase 4
37 Antiemetics Phase 4
38 Adrenergic beta-Agonists Phase 4
39 Adrenergic alpha-Agonists Phase 4
40 Vasoconstrictor Agents Phase 4
41 Anti-Asthmatic Agents Phase 4
42 Epinephryl borate Phase 4
43 Adrenergic Agonists Phase 4
44 Bronchodilator Agents Phase 4
45 Sympathomimetics Phase 4
46 Mydriatics Phase 4
47 glucocorticoids Phase 4
48 BB 1101 Phase 4
49 Anesthetics, Local Phase 4
50 Hemostatics Phase 4

Interventional clinical trials:

(show top 50) (show all 435)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Unknown status NCT02860429 Phase 4 Cinobufacini injection;chemotherapy
2 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
3 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
4 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
5 A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate Completed NCT00793871 Phase 4 Sunitinib Malate (SU011248)
6 Assessment the Effect of Medium-Calorie TPN on Patients With Gastrointestinal Cancer Undergoing Surgery Completed NCT01700062 Phase 4
7 A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
8 Muscle Relaxation During Open Upper Abdominal Surgery - Can the Surgical Conditions be Optimized? Completed NCT02140593 Phase 4 Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
9 Comparing With Traditional Nitrogen Calorie Parenteral Nutrition Support, the Impact of Low Calorie and Low Nitrogen Intake on the Clinical Outcome of Gastrointestinal Postoperative Patients, Multicentre Post-Marketing Clinical Study Completed NCT00247338 Phase 4 low calorie, low nitrogen parenteral nutrition for patient with NRS score 3
10 Glargine Insulin Versus Continous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) Completed NCT02216799 Phase 4 Glargine Insulin;Regular insulin
11 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
12 The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study Completed NCT01552291 Phase 4 Placebo
13 Comparison of Thromboembolic Events in Patients Undergoing Gastrointestinal Cancer Surgery and Thromboprophylactic Treatment With Two Enoxaparin Formulations (ENOXA® vs Lovenox®) Recruiting NCT02444572 Phase 4 Enoxaparin 4000 IU
14 Efficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
15 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Active, not recruiting NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
16 Randomized Controlled Trial of Hemostatic Powder Versus Optimal Clinical Management for the Treatment of Upper Gastrointestinal Bleeding From Tumor Lesions Not yet recruiting NCT02820077 Phase 4
17 Clinical Trial on Ganoderma Spore Lipids Combined With Chemo in Patients With G.I. Cancers Unknown status NCT02785523 Phase 3 Ganoderma Spore Lipids;Placebo;Chemotherapy
18 A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Unknown status NCT03303495 Phase 3 CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
19 Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization for the Treatment of Colorectal Liver Metastases (SIM Trial) Unknown status NCT02208804 Phase 2, Phase 3
20 Endoscopic Ultrasonography Guided Fine Needle Biopsy (EUS-FNB) vs. Single-incision Needle-knife (SINK) Biopsy for Diagnosis of Upper Gastrointestinal Subepithelial Lesions Unknown status NCT02866045 Phase 3
21 Immunonutrition to Improve Quality of Life of Upper Gastrointestinal Cancer Patients Undergoing Oncological Treatment Completed NCT01423799 Phase 3
22 Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery Completed NCT00826410 Phase 3
23 A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer Completed NCT00486954 Phase 3 Lapatinib;Paclitaxel
24 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
25 Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer: A Multicenter Randomized Clinical Trial Completed NCT02664974 Phase 3
26 A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Completed NCT01996306 Phase 3 CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);CPT-11 (Irinotecan);Capecitabine
27 A Clinical Randomized Control Trial of Combination TACE With and Without Low-molecular-weight Heparin in Hepatocellular Carcinoma Completed NCT00827554 Phase 2, Phase 3 LMWH
28 Monosialotetrahexosylganglioside Sodium Injection for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
29 Randomized Trial Comparing Drainage Versus no Drainage Following Rectal Excision With Low Anastomosis for Rectal Cancer Completed NCT01269567 Phase 3
30 A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed NCT00513357 Phase 3 Melatonin;Placebo
31 A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma Completed NCT00052962 Phase 3
32 A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Recruiting NCT03464305 Phase 3 acetylsalicylic acid;Placebo
33 Perioperative Chemotherapy With FOLFIRINOX Regimen or FLOT Regimen for Resectable Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial Recruiting NCT04393584 Phase 2, Phase 3 Irinotecan;5-FU;Leucovorin;Oxaliplatin;Docetaxel
34 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
35 An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer Active, not recruiting NCT02322593 Phase 3 TAS-118 plus Oxaliplatin;S-1 plus Cisplatin
36 A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC). Active, not recruiting NCT02753127 Phase 3 Napabucasin;Fluorouracil;Leucovorin;Irinotecan;Bevacizumab
37 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel;Gemcitabine
38 A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
39 A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer Not yet recruiting NCT03889626 Phase 3 Apatinib;Capecitabine
40 A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery Terminated NCT00254436 Phase 3 Procrit (epoetin alfa)
41 A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
42 An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) Terminated NCT01009593 Phase 3 ABT-869;Sorafenib
43 Effect of 3 Day Pre-operative Immunonutrition Regimen on Clinical Outcome in Well-nourished Patients With Gastrointestinal Cancer Undergoing Surgery , a Randomised Double-blind Controlled Trial Terminated NCT01023412 Phase 3
44 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
45 A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients Terminated NCT00516269 Phase 3 Methylphenidate;Placebo
46 Does Radiation Therapy Adversely Affect the Immune System, and Can Acupuncture Ameliorate the Effect? A Pilot Study Withdrawn NCT01422928 Phase 3
47 Study of Dihydropyrimidine Dehydrogenase for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer Unknown status NCT01608646 Phase 2 S-1 plus oxaliplatin
48 Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Liver Metastases From Gastrointestinal Tumors and Pancreatic Carcinoma Unknown status NCT02233205 Phase 1, Phase 2 platinum and gemcitabine
49 Phase II Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Unresectable Esophageal Cancer Unknown status NCT03187314 Phase 2 Radiation;SHR-1210
50 Celiac Plexus Radiosurgery for Pain Management in Advanced Cancer Patients - a Phase II Trial Unknown status NCT02356406 Phase 2

Search NIH Clinical Center for Gastrointestinal Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Imatinib mesylate

Genetic Tests for Gastrointestinal Carcinoma

Anatomical Context for Gastrointestinal Carcinoma

MalaCards organs/tissues related to Gastrointestinal Carcinoma:

Liver, Testes, Colon, Pancreas, Lung, Breast, Small Intestine

Publications for Gastrointestinal Carcinoma

Articles related to Gastrointestinal Carcinoma:

(show top 50) (show all 840)
# Title Authors PMID Year
[Correlation of expression of P-glycoprotein and inhibitor of apoptosis proteins to chemosensitivity in gastrointestinal carcinoma tissues]. 61 54
19000447 2008
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. 61 54
17848752 2007
Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients. 61 54
16034560 2006
Relationship between immunohistochemical evaluation of thymidylate synthase and proliferating cell nuclear antigen labeling index in gastrointestinal carcinoma. 54 61
15547732 2004
[CK20 mRNA expression in peripheral blood of patients with gastrointestinal carcinoma and its clinical significance]. 54 61
15522189 2004
Molecular detection of disseminated tumor cells in the peripheral blood in patients with gastrointestinal cancer. 61 54
12684893 2003
Gastrointestinal metastasis to the breast. 61 54
12464875 2002
Immunohistochemical detection of carcinoembryonic antigen in esophageal carcinomas: a comparison with other gastrointestinal neoplasms. 61 54
12168881 2002
Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM). 54 61
11080501 2001
Functional expression of CD11a on CD8+ cells is suppressed in regional lymph nodes with cancer involvement in patients with gastrointestinal carcinoma. 54 61
8859180 1996
Clinical evaluation of M43: a novel cancer-associated mucin epitope. 61 54
7684947 1993
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. 61 54
1569446 1992
Small Bowel Gastrointestinal Stromal Tumor as a Gateway for Streptococcus anginosus Causing Multiple Liver Abscesses. 61
32494319 2020
Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies. Revised version. 61
32396659 2020
Methods that Assist Traction during Endoscopic Submucosal Dissection of Superficial Gastrointestinal Cancers: A Systematic Literature Review. 61
31914722 2020
Endoscopic full-thickness resection of early colorectal neoplasms using an endoscopic submucosal dissection knife: a retrospective multicenter study. 61
32355878 2020
The effect of scissor-type versus non-scissor-type knives on the technical outcomes in endoscopic submucosal dissection for superficial esophageal cancer: a multi-center retrospective study. 61
31617891 2020
Learning Curve for Endoscopic Submucosal Dissection With an Untutored, Prevalence-Based Approach in the United States. 61
31220645 2020
Hemorrhage control during gastric endoscopic submucosal dissection: Techniques using uncovered knives. 61
32055690 2020
Cathepsin S as a target in gastric cancer. 61
31929878 2020
A ruptured jejunal gastrointestinal stromal tumor with hemoperitoneum mimicking ovarian carcinoma. 61
32055272 2020
Carcinoid Tumor: Advances in Treatment Options. 61
32064213 2020
Efficacy of scissor-type knives for endoscopic mucosal dissection of superficial gastrointestinal neoplasms. 61
31120558 2020
Generation of magnifying endoscopic images of gastric neoplasms based on an all-in-focus algorithm. 61
31334881 2020
Predicting outcomes in colorectal endoscopic submucosal dissection: a United States experience. 61
30725255 2019
Feasibility of robotic resection of gastrointestinal stromal tumors along the entire gastrointestinal tract. 61
30019164 2019
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. 61
31239549 2019
Clinical impact of periodontal disease on postoperative complications in gastrointestinal cancer patients. 61
31332612 2019
A Comparison of Biopsy and Mucosal Swab Specimens for Examining the Microbiota of Upper Gastrointestinal Carcinoma. 61
31519703 2019
Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort. 61
31314927 2019
Correlation of molecular and morphological features of appendiceal epithelial neoplasms. 61
31111538 2019
An Epithelioid Gastrointestinal Stromal Tumor of the Stomach With Strong Expression of Keratin: Clinicopathologic Correlation and Follow-up Post-Imatinib Therapy. 61
28362703 2019
Modular laser-based endoluminal ablation of the gastrointestinal tract: in vivo dose-effect evaluation and predictive numerical model. 61
30456508 2019
Early postoperative intraperitoneal chemotherapy for lower gastrointestinal neoplasms with peritoneal metastasis: a systematic review and critical analysis. 61
31667329 2019
"-Omas" presenting as "-itis": acute inflammatory presentations of common gastrointestinal neoplasms. 61
30719599 2019
Systematic review of anorectal leiomyosarcoma: Current challenges and recent advances. 61
31523383 2019
Efficacy and safety of steroid in the prevention of esophageal stricture after endoscopic submucosal dissection: A network meta-analysis. 61
30566746 2019
Short-term outcomes of traction-assisted versus conventional endoscopic submucosal dissection for superficial gastrointestinal neoplasms: a systematic review and meta-analysis of randomized controlled studies. 61
31164139 2019
Gene expression profiling as a potential predictor between normal and cancer samples in gastrointestinal carcinoma. 61
31164955 2019
Prognostic value of paravertebral muscle density in patients with spinal metastases from gastrointestinal cancer. 61
30220027 2019
Management of adverse events related to endoscopic resection of upper gastrointestinal neoplasms: Review of the literature and recommendations from experts. 61
30994225 2019
Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis. 61
30763436 2019
Gastrointestinal juvenile-like (inflammatory/hyperplastic) mucosal polyps in neurofibromatosis type 1 with no concurrent genetic or clinical evidence of other syndromes. 61
30276464 2019
The Four Horsemen in Colon Cancer. 61
31662752 2019
Jejunal GIST: Hunting down an unusual cause of gastrointestinal bleed using double balloon enteroscopy. A case report. 61
31277041 2019
Pitfalls in the Interpretation of Publications about Endoscopic Submucosal Dissection of Early Gastric Cancer with Undifferentiated-Type Histology. 61
30650945 2019
Gastrointestinal carcinoma and sarcoma surgery. 61
31304420 2019
Linked color imaging for the detection of early gastrointestinal neoplasms. 61
31700545 2019
Gastrointestinal Carcinoma with Plasmacytoid Morphology: Positivity for c-MET, Arylsulfatase, and Markers of Epithelial-Mesenchymal Transition, as Indicators of Aggressivity. 61
31205468 2019
The Characteristics of Blue Laser Imaging and the Application in Diagnosis of Early Digestive Tract Cancer. 61
30803360 2019

Variations for Gastrointestinal Carcinoma

ClinVar genetic disease variations for Gastrointestinal Carcinoma:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CHEK2 NM_007194.4(CHEK2):c.470T>C (p.Ile157Thr)SNV risk factor 5591 rs17879961 22:29121087-29121087 22:28725099-28725099
2 ELN NM_000501.4(ELN):c.898A>T (p.Thr300Ser)SNV Uncertain significance 523433 rs766735416 7:73466262-73466262 7:74051932-74051932

Copy number variations for Gastrointestinal Carcinoma from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19435 1 150300000 155000000 Amplification Gastrointestinal cancer
2 119187 18 1 2900000 LOH TS Gastrointestinal cancer
3 119685 18 16100000 23300000 Deletion HRH4 Gastrointestinal cancer

Expression for Gastrointestinal Carcinoma

Search GEO for disease gene expression data for Gastrointestinal Carcinoma.

Pathways for Gastrointestinal Carcinoma

GO Terms for Gastrointestinal Carcinoma

Cellular components related to Gastrointestinal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.5 PTPRC ITGAL EPCAM CEACAM6 CEACAM5 CEACAM1
2 apical plasma membrane GO:0016324 9.17 MUC1 EPCAM CEACAM7 CEACAM6 CEACAM5 CEACAM1

Biological processes related to Gastrointestinal Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.85 PTPRC ITGAL CEACAM6 CEACAM1 CD44
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 TP53 PTPRC CD44
3 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.54 TP53 MUC1 CHEK2
4 replicative senescence GO:0090399 9.49 TP53 CHEK2
5 positive regulation of stem cell proliferation GO:2000648 9.48 PTPRC EPCAM
6 bone marrow development GO:0048539 9.43 TP53 PTPRC
7 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.43 ITGAL CEACAM6 CEACAM5
8 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.4 TP53 MUC1
9 response to gamma radiation GO:0010332 9.33 TP53 PTPRC CHEK2
10 negative regulation of T cell mediated cytotoxicity GO:0001915 9.32 PTPRC CEACAM1
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 TP53 MUC1 CHEK2
12 leukocyte migration GO:0050900 9.1 ITGAL EPCAM CEACAM6 CEACAM5 CEACAM1 CD44

Sources for Gastrointestinal Carcinoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....